View Older Stories View More Recent Stories

Dec 13, 2024 08:00AM Ainos Joins Webull Corporate Connect Service Platform to Enhance Investor Engagement
Dec 4, 2024 08:00AM Water Tower Research Underscores Ainos' Partnership With Taiwan Tanabe Seiyaku for VELDONA Manufacturing and Marketing
Dec 2, 2024 08:00AM Ainos, Inc. Announces Strategic Partnership with Taiwan Tanabe Seiyaku to Advance Manufacturing and Taiwan Market Promotion of Sjögren's Syndrome Drug
Nov 13, 2024 08:00AM Water Tower Research Highlights IRB Approval for the Ainos VELDONA Clinical Sjogren's Trial Alongside 3Q24 Earnings and Developments
Nov 8, 2024 08:02AM Ainos (AIMD) Takes Decisive Action to Protect Stockholder Interests and Combat Potential Illegal Trading Activities
Nov 8, 2024 08:00AM Ainos Takes Decisive Action to Protect Stockholder Interests and Combat Potential Illegal Trading Activities
Nov 6, 2024 04:30PM Ainos Reports Third Quarter 2024 Financial Results
Oct 28, 2024 08:00AM Ainos Expands Patent Portfolio With Strategic Shareholder’s Cutting-Edge Technology Assets
Oct 24, 2024 10:50AM Ainos Highlights VELDONA Clinical Advancements and Market Potential in Water Tower Research Spotlight Podcast
Oct 7, 2024 08:00AM Ainos Advances Healthcare and Industrial Innovations with AI Nose and VELDONA Technologies
Sep 25, 2024 08:03AM Ainos (AIMD) Receives IRB Approval From National Taiwan University Hospital for HIV-Oral Warts Clinical Trial
Sep 25, 2024 08:00AM Ainos, Inc. Receives IRB Approval From National Taiwan University Hospital for HIV-Oral Warts Clinical Trial, Highlighting Value of FDA-Designated Orphan Drug VELDONA
Sep 24, 2024 10:55AM Ainos Spotlighted in Water Tower Research Report on VELDONA Clinical Study for Sjogren’s Syndrome
Sep 20, 2024 08:00AM Water Tower Research Highlights Ainos VELDONA Clinical Trial for HIV+ Patients with Oral Warts
Sep 17, 2024 08:09AM Ainos (AIMD) to Initiate Taiwan Clinical Study for VELDONA
Sep 17, 2024 08:00AM Ainos Announced Plan to Initiate Taiwan Clinical Study for VELDONA as Potential Treatment of Oral Warts in HIV-Seropositive Patients, an Orphan Drug Designated by the FDA
Sep 3, 2024 08:35AM Ainos (AIMD) Secures Taiwan Invention Patent and Advances Global Patent Protection for VELDONA, a Breakthrough in Coronavirus Treatment and Prevention
Sep 3, 2024 08:30AM Ainos Secures Taiwan Invention Patent and Advances Global Patent Protection for VELDONA, a Breakthrough in Coronavirus Treatment and Prevention
Aug 27, 2024 08:30AM Ainos to Participate in H.C. Wainwright 26th Annual Global Investment Conference
Aug 26, 2024 08:30AM Ainos CEO Highlights AI Nose Achievements and Upcoming 2H 2024 Milestones in Shareholder Letter
Aug 19, 2024 09:17AM Ainos (AIMD) Unveils AI Nose Breakthrough that Revolutionizes Smart Manufacturing Factory Automation and Manufacturing Safety
Aug 19, 2024 09:15AM Ainos Unveils AI Nose Breakthrough that Revolutionizes Smart Manufacturing Factory Automation and Manufacturing Safety
Aug 12, 2024 08:00AM Ainos to Participate in Fireside Chat with Water Tower Research on August 22, 2024
Aug 9, 2024 04:17PM Ainos (AIMD) Secures Exclusive Multi-Regions Invention Patent Licenses from Strategic Partner to Bolster AI Nose and Point-Of-Care Testing
Aug 9, 2024 04:15PM Ainos Secures Exclusive Multi-Regions Invention Patent Licenses from Strategic Partner to Bolster AI Nose and Point-Of-Care Testing
Aug 6, 2024 08:30AM Ainos Concludes Growth Financing From Lind Partners
Aug 5, 2024 04:15PM Ainos Reports Second Quarter 2024 Financial Results
Jul 23, 2024 09:30AM Ainos Enrolls First Subject for Clinical Study of VELDONA-Based Animal FCGS Drug
Jun 14, 2024 08:04AM Ainos (AIMD) Unveils Critical Progress in Ainos Flora Clinical Trials and Next-Gen Plans Powered by NVIDIA CUDA
Jun 14, 2024 02:00AM Ainos Unveils Critical Progress in Ainos Flora Clinical Trials and Next-Gen Plans Powered by NVIDIA CUDA
May 15, 2024 08:00AM Ainos to Initiate Clinical Study of New Potential VELDONA-Based Animal Drug, Expanding VELDONA's Potential Market
May 13, 2024 04:10PM Ainos Reports First Quarter 2024 Financial Results
May 7, 2024 08:00AM Ainos Raises $9 Million in Growth Capital with Existing Shareholder
Mar 8, 2024 04:20PM Ainos Reports Full Year 2023 Financial Results
Feb 5, 2024 09:05AM Ainos (AIMD) Submits Clinical Hold Complete Response to US FDA to Resolve the Deficiencies on Investigational New Drug Phase II Trial of its VELDONA Formulation Against Mild COVID-19 Symptoms
Feb 5, 2024 09:00AM Ainos Submits Clinical Hold Complete Response to US FDA to Resolve the Deficiencies on Investigational New Drug Phase II Trial of its VELDONA Formulation Against Mild COVID-19 Symptoms
Jan 24, 2024 09:03AM Ainos (AIMD) Receives $1.75M Follow-On Funding
Jan 24, 2024 09:00AM Ainos Announces $1.75 Million Follow-On Funding
Jan 2, 2024 09:02AM Ainos (AIMD) Regains Nasdaq Compliance
Jan 2, 2024 09:00AM Ainos Regains Compliance with Nasdaq Minimum Bid Price Requirement
Dec 26, 2023 09:03AM Ainos (AIMD), Nisshinbo Micro Devices and Inabata Initiate Phase 2 of VOC Co-development Powered by AI Nose, Accelerating the Digitalization of Smell
Dec 26, 2023 08:00AM Ainos, Nisshinbo Micro Devices and Inabata Initiate Phase 2 of VOC Co-development Powered by AI Nose, Accelerating the Digitalization of Smell
Dec 12, 2023 08:02AM Ainos (AIMD) Announces 1:5 Reverse Stock Split
Dec 12, 2023 08:00AM Ainos, Inc. Announces Stock Consolidation
Nov 28, 2023 08:30AM Ainos Announces Successful Manufacturing of VELDONA GMP Clinical Batch by Swiss Pharmaceutical
Nov 21, 2023 08:32AM Ainos (AIMD) Reports Positive Data Reported from its Clinical Studies for VELDONA
Nov 21, 2023 08:30AM Ainos Announces Positive Data Reported from its Clinical Studies for VELDONA as Potential Treatment of Oral Warts in HIV-Seropositive Patients, an Orphan Drug Designated by the FDA
Nov 9, 2023 04:30PM Ainos Reports Third Quarter 2023 Financial Results
Nov 6, 2023 08:03AM Ainos (AIMD) Signs MoU for Contract Clinical Trials to Conduct Clinical Study of Potential New Animal Drug Based on VELDONA
Nov 6, 2023 08:00AM Ainos Signs MoU for Contract Clinical Trials to Conduct Clinical Study of Potential New Animal Drug Based on VELDONA
View More Recent Stories View Older Stories